

214/04

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 11, 2003 <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b> Prior Application Number 09/645,879 Prior Appl. Filing Dat 08/25/2000 First Nam d Inv ntor Ping HUANG Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number 038602-1618	
Sheet	1	of	1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
[Signature]	A1	5,710,173	A	TANG et al.	01-20-1998	class 514-447

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
[Signature]	A2	WO	98/56376	A1	SUGEN, INC.	12-17-1998		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
[Signature]	A3	LEE et al., "Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells," PubMed Abstract 12110500, <u>Eur. J. Cancer</u> , July 2002, pp. 1526-1534, Vol. 38, No. 11		—
	A4	TSENG et al., "Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells," PubMed Abstract 12049842, <u>Toxicology</u> , June 14, 2002, pp. 123-142, Vol. 175, No. 1-3		—
	A5	UKKOLA et al., "Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities," PubMed Abstract 12028501, <u>J. Intern. Med.</u> , June 2002, pp. 467-475, Vol. 251, No. 6		—
	A6	XU et al., "Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms," PubMed Abstract 12134145, <u>Nat. Immuno.</u> , August 2002, pp. 764-771, Vol. 3, No. 8		—
[Signature]	A7	JENKINS et al., "Solid-phase synthesis and biochemical studies of O-boranophosphopeptides and O-dithiophosphopeptid," PubMed Abstract 12047178, <u>J. Am. Chem. Soc.</u> , June 12, 2002, pp. 6584-6593, Vol. 124, No. 23		—

Examiner Signature [Signature]	Date Considered	8/18/04
--------------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450,